SRTS Overview

Quarterly Performance: Sensus Healthcare reported a quarterly loss of $0.06 per share, better than the expected loss of $0.12, but down from earnings of $0.07 per share a year ago. The company also posted revenues of $6.88 million, exceeding estimates by 48.36%.

Stock Outlook: Despite the earnings surprise, Sensus Healthcare shares have declined by 46.7% this year, and the stock currently holds a Zacks Rank #4 (Sell), indicating expected underperformance in the near future.

Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, with a fiscal year estimate of -$0.43 on $26.34 million in revenues, reflecting an unfavorable trend in earnings estimate revisions.

Industry Context: The Medical - Instruments industry is currently ranked in the top 35% of Zacks industries, suggesting that overall industry performance could significantly influence Sensus Healthcare's stock performance moving forward.

Recognition of Sensus Healthcare: Sensus Healthcare has been named No. 72 on TIME's list of America's Growth Leaders of 2026, highlighting its revenue growth, financial stability, and stock performance over the past five years.

Focus on Non-Invasive Treatments: The company specializes in non-invasive treatments for skin conditions, particularly non-melanoma skin cancer and keloids, utilizing its superficial radiation therapy (SRT and IG-SRT) technology.

CEO's Statement: Joe Sardano, CEO of Sensus Healthcare, emphasized the importance of customer service and patient outcomes in achieving this recognition, crediting the support from physicians and patients over the past 15 years.

Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties, indicating that actual results may differ from expectations due to various factors affecting the business and industry.